pt en es

Reagents and instruments for immunology, cell biology and molecular biology.

Withaferin A [5119-48-2]

Print

Cat# HY-N2065-1mg

Size : 1mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description

Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits NF-kB activation and targets vimentin, with potent antiinflammatory and anticancer activities. Withaferin A is an inhibitor of endothelial protein C receptor (EPCR) shedding.

IC₅₀ & Target^[1]

NFκB

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	32.7 nM Compound: 1; WA	Antiproliferative activity against cisplatin-sensitive human A2780 cells measured after 96 hrs by MTT assay Antiproliferative activity against cisplatin-sensitive human A2780 cells measured after 96 hrs by MTT assay	[PMID: 31008605]
A549	IC₅₀	0.02 μg/mL Compound: WA	Cytotoxicity against human A549 cells by MTT method Cytotoxicity against human A549 cells by MTT method	[PMID: 17417907]
A549	IC₅₀	1.5 μM Compound: 9	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	10.1 μM Compound: 1; WA	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	6.6 μM Compound: 1; WA	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	6.6 μM Compound: 9	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
ACHN	IC₅₀	> 2000 nM Compound: 2a	Sensitization of TRAIL-induced apoptosis in human ACHN cells assessed as reduction in cell viability preincubated for 2 hrs followed by addition of TRAIL measured after 18 hrs by MTS assay Sensitization of TRAIL-induced apoptosis in human ACHN cells assessed as reduction in cell viability preincubated for 2 hrs followed by addition of TRAIL measured after 18 hrs by MTS assay	[PMID: 28257574]
ARPE-19	IC₅₀	37 nM Compound: 1; WA	Cytotoxicity against human ARPE19 cells measured after 96 hrs by MTT assay Cytotoxicity against human ARPE19 cells measured after 96 hrs by MTT assay	[PMID: 31008605]
B16-F10	IC₅₀	0.29 μM Compound: 16	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay	[PMID: 22098611]
BXPC-3	IC₅₀	2.78 μM Compound: 46; WA	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay	[PMID: 31663736]
C3H 10T1/2	IC₅₀	4.9 μM Compound: 1	Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA	[PMID: 26169123]
DU-145	IC₅₀	2.5 μM Compound: 1	Cytotoxicity against human DU145 cells after 24 hrs by FMCA Cytotoxicity against human DU145 cells after 24 hrs by FMCA	[PMID: 26169123]
HCT-116	IC₅₀	3.7 μM Compound: 75	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33445154]
HEK-293T	IC₅₀	299 nM Compound: 1	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by resazurin dye based Alamar blue assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by resazurin dye based Alamar blue assay	[PMID: 29537263]
HFF	EC₅₀	> 6800 nM Compound: 9	Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
HFF	IC₅₀	> 6.8 μM Compound: 22	Cytotoxicity against human HFF cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human HFF cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
HFF	IC₅₀	> 6.8 μM Compound: 8, WA	Cytotoxicity against HFF assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against HFF assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
HaCaT	IC₅₀	0.5 μM Compound: 1	Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay	[PMID: 26169123]
HeLa	IC₅₀	2.3 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	3 μM Compound: 1; WA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	3 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	6.3 μM Compound: 1; WA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Hep 3B2	IC₅₀	0.06 μg/mL Compound: WA	Cytotoxicity against human Hep3B cells by MTT method Cytotoxicity against human Hep3B cells by MTT method	[PMID: 17417907]
HepG2	IC₅₀	0.06 μg/mL Compound: WA	Cytotoxicity against human HepG2 cells by MTT method Cytotoxicity against human HepG2 cells by MTT method	[PMID: 17417907]
LNCaP	EC₅₀	870 nM Compound: 9	Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
LNCaP	IC₅₀	0.87 μM Compound: 22	Cytotoxicity against human LNCAP cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human LNCAP cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
LNCaP	IC₅₀	0.87 μM Compound: 8, WA	Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
MCF7	IC₅₀	0.05 μg/mL Compound: WA	Cytotoxicity against human MCF7 cells by MTT method Cytotoxicity against human MCF7 cells by MTT method	[PMID: 17417907]
MCF7	IC₅₀	0.57 μM Compound: 22	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
MCF7	IC₅₀	0.57 μM Compound: 8, WA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
MCF7	IC₅₀	0.6 μM Compound: 9	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	1.3 μM Compound: 1; WA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	1.3 μM Compound: withaferin A	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 26492982]
MCF7	IC₅₀	3.6 μM Compound: 1; WA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	3.6 μM Compound: 9	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	6.3 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by FMCA Cytotoxicity against human MCF7 cells after 24 hrs by FMCA	[PMID: 26169123]
MDA-MB-231	IC₅₀	0.02 μg/mL Compound: WA	Cytotoxicity against human MDA-MB-231 cells by MTT method Cytotoxicity against human MDA-MB-231 cells by MTT method	[PMID: 17417907]
MDA-MB-231	IC₅₀	0.5 μM Compound: withaferin A	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 26492982]
MDA-MB-231	IC₅₀	0.54 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 24273633]
MIA PaCa-2	IC₅₀	2.93 μM Compound: 46; WA	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTS assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTS assay	[PMID: 31663736]
MM1.S	IC₅₀	53 nM Compound: 1	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
MRC5	IC₅₀	0.07 μg/mL Compound: WA	Cytotoxicity against human MRC5 cells by MTT method Cytotoxicity against human MRC5 cells by MTT method	[PMID: 17417907]
MRC5	IC₅₀	0.2 μM Compound: Withaferin A	Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay	[PMID: 23252848]
MRC5	IC₅₀	2.7 μM Compound: 1	Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay	[PMID: 24273633]
Multiple myeloma cancer stem cell	IC₅₀	649.7 nM Compound: WFA	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
NCI-H460	IC₅₀	< 0.4 μM Compound: 22	Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
NCI-H460	IC₅₀	< 0.4 μM Compound: 8, WA	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
NCI-H929	IC₅₀	0.25 μM Compound: 1, WA	Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay	[PMID: 24625088]
PANC-1	IC₅₀	1.24 μM Compound: 46; WA	Antiproliferative activity against human PANC1 cells after 48 hrs by MTS assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTS assay	[PMID: 31663736]
PANC-1	IC₅₀	1.6 μM Compound: 1	Cytotoxicity against human PANC1 cells after 24 hrs by FMCA Cytotoxicity against human PANC1 cells after 24 hrs by FMCA	[PMID: 26169123]
PC-3	EC₅₀	410 nM Compound: 9	Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
PC-3	IC₅₀	0.41 μM Compound: 8, WA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
PC-3M	IC₅₀	0.41 μM Compound: 22	Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
RPMI-8226	IC₅₀	1.6 μM Compound: 1	Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay	[PMID: 34445874]
RPMI-8226	IC₅₀	258 nM Compound: 1	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
SF-268	IC₅₀	< 0.4 μM Compound: 22	Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
SF-268	IC₅₀	< 0.4 μM Compound: 8, WA	Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
SK-MEL-28	IC₅₀	1 μM Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 24273633]
SK-MEL-28	IC₅₀	4 μM Compound: 16	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 22098611]
SW480	IC₅₀	4.9 μM Compound: 75	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33445154]
U-251	IC₅₀	0.69 μM Compound: Withaferin A	Cytotoxicity against human U251 cells after 72 hrs by MTS assay Cytotoxicity against human U251 cells after 72 hrs by MTS assay	[PMID: 23252848]
U-87MG ATCC	IC₅₀	1.1 μM Compound: Withaferin A	Cytotoxicity against human U87 cells after 72 hrs by MTS assay Cytotoxicity against human U87 cells after 72 hrs by MTS assay	[PMID: 23252848]
Vero	IC₅₀	1.3 μM Compound: 1; WA	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	1.3 μM Compound: 9	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	1.7 μM Compound: 9	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	6.6 μM Compound: 1; WA	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]

In Vitro

Withaferin A has antiinflammatory activity, and potently inhibits NF-kB activation by preventing the TNF-induced activation of Ik-B kinase beta via a thioalkylation-sensitive redox mechanism^[1].
Withaferin A also has anticancer activity. Withaferin A targets the IF protein vimentin, causes aggregation of vimentin filaments in bovine aortic endothelial cells (BAECs) at 3 μM, and induces vimentin fragmentation in endothelial cells at 10 μM^[2].
Withaferin A (0.5, 1.5 μM) alone or incombination with cisplatin (CIS) dose-dependently reduces tumorigenic potential of ALDH1 positive cancer stem cells (CSCs)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Withaferin A (2 mg/kg, i.p.) shows potent angiogenesis inhibitory activity via vimentin in mice^[2]. Withaferin A (2 mg/kg) combined with cisplatin (CIS) regulates the expression of ALDH1 marker, and downregulates the expression of securin in tumors collected from mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

470.60

Formula

C₂₈H₃₈O₆

CAS No.

5119-48-2

Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@](CC[C@@]1(C)[C@@]2(00)CC[C@]1(00)[C@@H]([C@@](O3)(00)CC(C)=C(CO)C3=O)C)(00)[C@@]2(00)C4)(C(C=C5)=O)[C@@]6([C@H]5O)[C@@H]4O6

Structure Classification

Steroids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (106.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1249 mL	10.6247 mL	21.2495 mL
5 mM	0.4250 mL	2.1249 mL	4.2499 mL
10 mM	0.2125 mL	1.0625 mL	2.1249 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

Purity & Documentation

Purity: 99.92%

Data Sheet (283 KB) SDS (393 KB)

COA (254 KB) LCMS (91 KB)

Handling Instructions (2659 KB)

References

[1]. Kaileh M, et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007 Feb 16;282(7):4253-64. Epub 2006 Dec 6. [Content Brief]

[2]. Bargagna-Mohan P, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 2007 Jun;14(6):623-34. [Content Brief]

[3]. Kakar SS, et al. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017 Aug 10;8(43):74494-74505. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

HY-N0840-1mg

Bruceantin [41451-75-6]

1mg

HY-N2065-5mg

Withaferin A [5119-48-2]

5mg

Withaferin A [5119-48-2]

Cat# HY-N2065-1mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

Withaferin A Related Antibodies

You might also be interested by the following products: